Clinical studies on penetration of biapenem to postoperative peritoneal exudate

K. Ishibiki, Y. Saikawa, S. Shibata

Research output: Contribution to journalArticle

Abstract

We studied biapenem (BIPM), a new carbapenem antibiotic, in terms of postoperative penetration into peritoneal exudate. We measured daily concentration of BIPM in peritoneal exudate after radical gastrectomy for gastric cancer or gastric leiomyosarcoma for 3 days. BIPM was administered by intravenous drip infusion at a dose of 0.3 g twice a day. The average concentrations in peritoneal exudate in 3 patients were 0.68, 0.33 and 0.11 μg/ml on days 1, 2 and 3, respectively. No side effects and no abnormal laboratory findings were observed.

Original languageEnglish
Pages (from-to)683-685
Number of pages3
JournalChemotherapy
Volume42
Issue numberSUPPL. 4
Publication statusPublished - 1994

Fingerprint

biapenem
Exudates and Transudates
Intravenous Infusions
Stomach Neoplasms
Carbapenems
Leiomyosarcoma
Gastrectomy
Clinical Studies

ASJC Scopus subject areas

  • Pharmacology

Cite this

Ishibiki, K., Saikawa, Y., & Shibata, S. (1994). Clinical studies on penetration of biapenem to postoperative peritoneal exudate. Chemotherapy, 42(SUPPL. 4), 683-685.

Clinical studies on penetration of biapenem to postoperative peritoneal exudate. / Ishibiki, K.; Saikawa, Y.; Shibata, S.

In: Chemotherapy, Vol. 42, No. SUPPL. 4, 1994, p. 683-685.

Research output: Contribution to journalArticle

Ishibiki, K, Saikawa, Y & Shibata, S 1994, 'Clinical studies on penetration of biapenem to postoperative peritoneal exudate', Chemotherapy, vol. 42, no. SUPPL. 4, pp. 683-685.
Ishibiki K, Saikawa Y, Shibata S. Clinical studies on penetration of biapenem to postoperative peritoneal exudate. Chemotherapy. 1994;42(SUPPL. 4):683-685.
Ishibiki, K. ; Saikawa, Y. ; Shibata, S. / Clinical studies on penetration of biapenem to postoperative peritoneal exudate. In: Chemotherapy. 1994 ; Vol. 42, No. SUPPL. 4. pp. 683-685.
@article{9f95d1fea62844babb05607ccb885f28,
title = "Clinical studies on penetration of biapenem to postoperative peritoneal exudate",
abstract = "We studied biapenem (BIPM), a new carbapenem antibiotic, in terms of postoperative penetration into peritoneal exudate. We measured daily concentration of BIPM in peritoneal exudate after radical gastrectomy for gastric cancer or gastric leiomyosarcoma for 3 days. BIPM was administered by intravenous drip infusion at a dose of 0.3 g twice a day. The average concentrations in peritoneal exudate in 3 patients were 0.68, 0.33 and 0.11 μg/ml on days 1, 2 and 3, respectively. No side effects and no abnormal laboratory findings were observed.",
author = "K. Ishibiki and Y. Saikawa and S. Shibata",
year = "1994",
language = "English",
volume = "42",
pages = "683--685",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Clinical studies on penetration of biapenem to postoperative peritoneal exudate

AU - Ishibiki, K.

AU - Saikawa, Y.

AU - Shibata, S.

PY - 1994

Y1 - 1994

N2 - We studied biapenem (BIPM), a new carbapenem antibiotic, in terms of postoperative penetration into peritoneal exudate. We measured daily concentration of BIPM in peritoneal exudate after radical gastrectomy for gastric cancer or gastric leiomyosarcoma for 3 days. BIPM was administered by intravenous drip infusion at a dose of 0.3 g twice a day. The average concentrations in peritoneal exudate in 3 patients were 0.68, 0.33 and 0.11 μg/ml on days 1, 2 and 3, respectively. No side effects and no abnormal laboratory findings were observed.

AB - We studied biapenem (BIPM), a new carbapenem antibiotic, in terms of postoperative penetration into peritoneal exudate. We measured daily concentration of BIPM in peritoneal exudate after radical gastrectomy for gastric cancer or gastric leiomyosarcoma for 3 days. BIPM was administered by intravenous drip infusion at a dose of 0.3 g twice a day. The average concentrations in peritoneal exudate in 3 patients were 0.68, 0.33 and 0.11 μg/ml on days 1, 2 and 3, respectively. No side effects and no abnormal laboratory findings were observed.

UR - http://www.scopus.com/inward/record.url?scp=0028576810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028576810&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028576810

VL - 42

SP - 683

EP - 685

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - SUPPL. 4

ER -